{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0852","upperLimit":"0.7551","value":"0.3750"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success proportion will be calculated. If patients are censored prior to 18 months post registration, a Kaplan Meier (Kaplan, E. and Meier, P., 1958) estimate for PFS18 along with the 95% confidence intervals will be reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"INDUCTION (COURSES 1-4): Patients receive ixazomib citrate PO on days 1, 8, and 15, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days (courses 1-3) and 56 days (course 4) for up to 4 courses in the absence of disease progression or unacceptable toxicity.\n\n\\>\n\n\\> TRANSPLANTATION (COURSE 5): Between 2-4 weeks following Induction, patients undergo ASCT.\n\n\\>\n\n\\> CONSOLIDATION (COURSES 6-9): Beginning 60-120 days following ASCT, patients receive ixazomib citrate, pomalidomide, and dexamethasone as in Induction. Treatment repeats every 28 days (courses 6-8) and 56 days (course 9) for up to 4 courses in the absence of disease progression or unacceptable toxicity.\n\n\\>\n\n\\> MAINTENANCE (COURSES 10+): Beginning 0-4 weeks following Consolidation, patients receive ixazomib citrate as in Induction. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\n\\>\n\n\\> Autologous Hematopoietic Stem Cell Transplantation: Undergo ASCT\n\n\\>\n\n\\> Dexamethasone: Given PO\n\n\\>\n\n\\> Ixazomib Citrate: Given PO\n\n\\>\n\n\\> Laboratory Biomarker Analysis: Correlative studies\n\n\\>\n\n\\> Pomalidomide: Given PO","id":"OG000","title":"Treatment (Ixazomib, Pomalidomide, Dexamethasone, ASCT)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"18 months","title":"Progression-free Survival at 18 Months (PFS18) Defined as the Proportion of Patients Alive and Free From Disease Progression at 18 Months From Study Entry","type":"PRIMARY","unitOfMeasure":"proportion of participants"}